Rubella is the contagious viral infection of the respiratory system. Rubella is also known as German measles. Rubella is not similar to measles, although they have similar characteristics such as red rushes, but they are caused by a different virus. Rubella virus causes joint pain, low-grade fever, sore throat and skin rash. About 25% to 50% of people infected with rubella virus do not experience any symptoms. Rubella virus spreads through the air or by close contact. It is usually spread when the person directly comes in contact with an infected person’s respiratory secretion such as mucus. Rubella can cause serious problems including the arthritis and bleeding problems. Rubella infection very serious during pregnancy, it can cause a variety of birth defects & miscarriage. Most serious problems occur because of rubella is harm to a baby. There is no specific treatment available for rubella. Rubella vaccination is recommended for prevention of rubella infection. Unvaccinated ladies face 90% chances of the fetus having congenital rubella syndrome. Symptomatic treatment is available to reduce the risk of complication and ease the symptoms. Paracetamol, ibuprofen, aspirin can be used to reduce high temperature and treat acne and pain.
High risk of complication in rubella infected pregnant women and the larger number of unvaccinated children & adults are the major factors which contribute to the growth of rubella treatment market. Increasing manufacturers focus on drug development for rare diseases, rising healthcare awareness, government programs to maintain pregnant women health are expected to be some other factor which propels the growth of rubella treatment market. Failure to vaccinating children against measles & rubella puts them at risk of severe health complications, such as brain damage, deafness, and blindness. Increasing failure of vaccination will boost the demand of drugs which are used for symptomatic treatment and, can indirectly contribute in the growth of rubella treatment market. No specific treatment is available for rubella infection, which is a major factor hampering the growth of rubella treatment market.
The global rubella treatment market is segmented on basis of drug type, route of administration and distribution channel:
Nonsteroidal anti-inflammatory drugs and analgesic drugs are used for rubella treatment or reduce symptoms. These drugs provide ease of pain, reduce itching and control fever due to rubella infection. Rubella infection is dangerous during pregnancy if a woman contract rubella up to 13 week of pregnancy there is a very high risk that baby can be affected with measles. Baby can develop problems such as sight or hearing loss.
Regionally, the global rubella treatment market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific Excluding China, China, and Middle East & Africa. North America is expected to lead the global market due to increasing drug manufacturing facilities and high awareness regarding infectious diseases. Europe also shows second highest growth in rubella treatment market due to strong laws and government guidelines regarding child and mother health. Moreover, the rubella treatment market in the Asia-Pacific region is expected to witness significant growth rate during the forecast period due to increasing government initiatives to reduce disease complication in children. More than 60% of the 21.5 million children who did not receive one dose vaccination in 2013 come from 6 counties India, Nigeria, Pakistan, Ethiopia, Indonesia, DR Congo.
Some of the players operating in the global rubella treatment market are Bayer AG, Novartis AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline PLC., Reckitt Benckiser Group plc, Endo International plc, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Merck & Company, Inc., Perrigo Company plc, Abbott Laboratories, Geri-Care Pharmaceuticals Corp., Kopran Ltd. and others.
The report covers exhaustive analysis on:
Absence of Vaccination against Rubella amongst Neonates in the developing countries to drive the Rubella Treatment Market
Persistence market Research says that the global rubella treatment market will escalate between 2020 and 2030.
Rubella is also known as “German Measles”. The symptoms of rubella (caused by rubella virus) include skin rash, sore throat, low-grade fever, and joint pain. Introduction of rubella vaccine is bound to drive the rubella treatment market going forward. Moreover, Governments are also taking up initiatives to create awareness about the dangers of rubella. This factor is also likely to drive the rubella treatment market further.
The outbreak of Covid-19 has suspended the research on the count of rubella treatment. The vaccination is also going slow. This scenario is expected to persist till mid-2021 (till Covid-19 vaccine would probably be in place).
North America leads the rubella treatment market due to growing manufacturing facilities herein along with higher awareness with regards to infectious diseases. Europe stands second with stern and strong guidelines regarding mother and child health. However, the future belongs to the Asia-Pacific and MEA, as research states that over 60% of the children adversely affected by rubella come from DR Congo, Indonesia, Ethiopia, Pakistan, Nigeria, and India.
The key players in the rubella treatment market include Grifols, S.A., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Biological E, Aurobindo Pharma, Vintage Labs, Sanofi, AstraZeneca, Amneal Pharmaceuticals LLC, Merck & Co., Inc., Bio Farma, and Dr. Reddy’s Laboratories Ltd.
On the growth front, Grifols, S.A., in Sep 2018, did receive approval from the US FDA for immune globulin (human) known as GamaSTAN for treating measles and HAV (Hepatitis Virus). Also, Takeda Pharmaceutical Company, in Jun 2017, did collaborate with Biological E for developing affordable combination vaccines inclusive of DTaP (diphtheria, tetanus, and acellular pertussis) and MR (measles-rubella) vaccines. Since then, Biological E did commercialize vaccine in China, India, and several middle- and low-income countries.